Fig. 3.

Repeated dosing of mitazalimab in OVA-rechallenged mice results in expansion of OVA-specific CD8⁺ T cells—Naïve hCD40tg mice were immunized with 200 µg OVA protein i.v. on 3 occasions, 7 days between. The mice were divided into different cohorts, wherein each cohort was given 100 µg mitazalimab i.p. at different dose regimens. One cohort received no mitazalimab treatment (OVA only). A subset of mice from each cohort was sacrificed once weekly for 6 weeks after the first immunization and spleens and blood collected for flow cytometry. a Overview of the experimental set-up, b frequency of OVA-specific (SIINFEKL-MHCI tetramer⁺) splenic CD8⁺ T cells, c representative FACS plots from two groups from the day 14 time point in b, d frequency of activated CD80⁺ CD86⁺ splenic DC (CD11c⁺ MHCII⁺), e frequency of activated CD80⁺ CD86⁺ splenic B cells (CD19⁺ MHCII⁺), f frequency of activated CD86⁺ circulating B cells. n = 3–4 per group in a–f. Statistical significance was analyzed by ordinary two-way ANOVA and Šídák’s multiple comparisons test in b, d–f. No relevant comparisons were significant in b. All error bars indicate ± SEM